Company news

Esperion Therapeutics, Inc. news in 2023

Esperion Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

December 12, 2023

Esperion Reports Third Quarter 2023 Financial Results

November 6, 2023

Esperion to Report Third Quarter 2023 Financial Results on November 7

October 23, 2023

Esperion Reports Second Quarter 2023 Financial Results

July 31, 2023

Esperion to Report Second Quarter 2023 Financial Results on August 1

July 16, 2023

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

June 27, 2023

Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

May 31, 2023

Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders

May 24, 2023

Esperion Reports First Quarter 2023 Financial Results

May 8, 2023

Esperion to Report First Quarter 2023 Financial Results May 9, 2023

April 24, 2023

Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC

April 18, 2023

Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

March 19, 2023

Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

February 20, 2023

Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC

February 19, 2023

Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023

February 6, 2023

Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results

January 7, 2023

Calls in 2023